	US 11,918,609 B2
	Stem cells for wound healing
Aernout Luttun, Zwevezele (BE); and Robert J. Deans, Riverside, CA (US)
Assigned to ABT HOLDING COMPANY, Cleveland, OH (US); and KATHOLIEKE UNIVERSITEIT LEUVEN, Leuven (BE)
Filed by ABT Holding Company, Cleveland, OH (US); and Katholieke Universiteit Leuven, Leuven (BE)
Filed on Apr. 5, 2021, as Appl. No. 17/222,460.
Application 17/222,460 is a continuation of application No. 15/043,171, filed on Feb. 12, 2016, granted, now 10,967,006.
Claims priority of provisional application 62/281,334, filed on Jan. 21, 2016.
Prior Publication US 2022/0031756 A1, Feb. 3, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/28 (2015.01); A61K 35/12 (2015.01); A61P 17/02 (2006.01); C12N 5/074 (2010.01)

CPC A61K 35/28 (2013.01) [A61K 35/12 (2013.01); A61P 17/02 (2018.01); C12N 5/0607 (2013.01); A01K 2207/12 (2013.01); A01K 2227/105 (2013.01); A01K 2267/03 (2013.01)]

15 Claims

1. A method to promote cutaneous burn healing in a subject by administering cells (I) in an effective amount and for a time sufficient to promote the cutaneous burn healing, wherein the cells (I) are not delivered from a functionalized substrate, wherein the cells (I) are non-embryonic non-germ cells that express CD90 and oct4 or telomerase, are not transformed, are not tumorigenic, and have a normal karyotype.